Primary cutaneous B-cell lymphoma: A clinical, histological, phenotypic and genotypic study of 21 cases

British Journal of Dermatology

Volumn 142, Issue 5, 2000, Pages 913-923

  Groonbaek K ^a,c   Mooller P H ^a   Nedergaard, T ^c   Thomsen, K ^d   Baadsgaard, O ^d   Hou Jensen, K ^b   Zeuthen, J ^c   Guldberg, P ^c   Ralfkiær, Elisabeth ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^d NONE

Author keywords

B cell lymphoma; Immunophenotyping

Indexed keywords

CD20 ANTIGEN; CD5 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIN D1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; RELAPSE; SKIN LYMPHOMA;

ADULT; AGED; AGED, 80 AND OVER; BCL-2-ASSOCIATED X PROTEIN; DNA METHYLATION; FEMALE; GENE DELETION; GENE EXPRESSION; GENES, BCL-2; GENES, P16; GENES, P53; GENOTYPE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS;

EID: 0038514614     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03471.x     Document Type: Article

References (48)

1. 1 Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-71.
2. 2 Willemze R, Beljaards RC, Meijer CJ, Rijlaarsdam JR. Classification of primary cutaneous lymphomas. Historical overview and perspectives. Dermatol 1994; 189 (Suppl. 2): 8-15.
3. 3 Sander CA, Kind P, Kaudewitz P et al. The Revised European-American Classification of Lymphoid Neoplasms (REAL): a new perspective for the classification of cutaneous lymphomas. J Cutan Pathol 1997; 24: 329-41.
4. 4 Isaacson PG, Norton AJ. Cutaneous lymphoma. In: Extranodal Lymphomas (Isaacson PG, Norton AJ, eds). New York: Churchill Livingstone, 1994: 172-6.
5. 5 Slater DN. MALT and SALT: the clue to cutaneous B-cell lymphoproliferative disease. Br J Dermatol 1994; 131: 557-61.
6. 6 Russell-Jones R. Primary cutaneous B-cell lymphoma: how useful is the new European Organization for Research and Treatment of Cancer (EORTC) classification? Br J Dermatol 1998; 139: 945-9.
7. 7 Cerroni L, Signoretti S, Hofler G et al. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol 1997; 21: 1307-15.
8. 8 Reed JC, Miyashita T, Krajewski S et al. Bcl-2 family proteins and the regulation of programmed cell death in leukemia and lymphoma. Cancer Treat Res 1996; 84: 31-72.
9. 9 Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: one gene - two products - two pathways. Trends Biochem Sci 1998; 23: 291-6.
10. 10 Pinyol M, Cobo F, Bea S et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91: 2977-84.
11. 11 Elenitoba-Johnson KS, Gascoyne RD, Lim MS et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998; 91: 4677-85.
12. 12 Koduru PR, Raju K, Vadmal V et al. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 1997; 90: 4078-91.
13. 13 Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 1987; 317: 1185-9.
14. 14 de Boer CJ, van Krieken JH, Schuuring E, Kluin PM. Bcl-1/cyclin D1 in malignant lymphoma. Ann Oncol 1997; 8 (Suppl. 2): 109-17.
15. 15 Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
16. 16 Gronbæk K, Nedergaard T, Andersen MK et al. Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb. Leukemia 1998; 12: 1266-71.
17. 17 Lauritzen AF, Moller PH, Nedergaard T et al. Apoptosis-related genes and proteins in Hodgkin's disease. APMIS 1999; 107: 636-44.
18. 18 Crescenzi M, Seto M, Herzig GP et al. Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. Proc Natl Acad Sci USA 1988; 85: 4869-73.
19. 19 Horsman DE, Gascoyne RD, Coupland RW et al. Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14;18) in follicular lymphoma. Am J Clin Pathol 1995; 103: 472-8.
20. 20 Klefstrom J, Franssila K, Peltomaki P et al. Major and minor breakpoint sites of chromosomal translocation t(14ev;18) in subtypes of non-Hodgkin's lymphomas. Leuk Res 1994; 18: 245-50.
21. 21 Guldberg P, Nedergaard T, Nielsen HJ et al. Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat 1997; 9: 348-55.
22. 22 Ueki K, Ono Y, Henson JW et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996; 56: 150-3.
23. 23 Hussussian CJ, Struewing JP, Goldstein AM et al. Germline p16 mutations in familial melanoma. Nature Genet 1994; 8: 15-21.
24. 24 Stranks G, Height SE, Mitchell P et al. Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 1995; 85: 893-901.
25. 25 Zeschnigk M, Lich C, Buiting K et al. A single-tube PCR test for the diagnosis of Angelman and Prader-Willi syndrome based on allelic methylation differences at the SNRPN locus. Eur J Hum Genet 1997; 5: 94-8.
26. 26 Herman JG, Graff JR, Myohanen S et al. Methylation-specific PCR. a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-6.
27. 27 Herman JG, Civin CI, Issa JP et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997; 57: 837-41.
28. 28 Merlo A, Herman JG, Mao L et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1995; 1: 686-92.
29. 29 Santucci M, Pimpinelli N, Arganini L. Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases. Cancer 1991; 67: 2311-26.
30. 30 Brice P, Cazals D, Mounier N et al. Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Étude des Lymphomes de l'Adulte. Leukemia 1998; 12: 213-19.
31. 31 Kurtin PJ, DiCaudo DJ, Habermann TM et al. Primary cutaneous large cell lymphomas. Morphologic, immunophenotypic, and clinical features of 20 cases. Am J Surg Pathol 1994; 18: 1183-91.
32. 32 Joly P, Vasseur E, Esteve E et al. Primary cutaneous medium and large cell lymphomas other than mycosis fungoides. An immunohistological and follow-up study on 54 cases. French Study Group for Cutaneous Lymphomas. Br J Dermatol 1995; 132: 506-12.
33. 33 A. predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-94.
34. 34 Vermeer MH, van Geelen FA, Haselen CW et al. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. Arch Dermatol 1996; 132: 1304-8.
35. 35 Willemze R, Meijer CJ. Classification of primary cutaneous B-cell lymphomas: EORTC classification or REAL classification? Br J Dermatol 1999; 141: 350-2.
36. 36 Pimpinelli N, Santucci M, Mori M et al. Primary cutaneous B-cell lymphoma: a clinically homogeneous entity? J Am Acad Dermatol 1997; 37: 1012-16.
37. 37 Neri A, Fracchiolla NS, Roscetti E et al. Molecular analysis of cutaneous B-and T-cell lymphomas. Blood 1995; 86: 3160-72.
38. 38 Cerroni L, Volkenandt M, Rieger E et al. bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas. J Invest Dermatol 1994; 102: 231-5.
39. 39 Bailey EM, Ferry JA, Harris NL et al. Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. Am J Surg Pathol 1996; 20: 1011-23.
40. 40 Ballesteros E, Osborne BM, Matsushima AY. CD5+ low-grade marginal zone B-cell lymphomas with localized presentation. Am J Surg Pathol 1998; 22: 201-7.
41. 41 Willis TG, Jadayel DM, Du MQ et al. Bcl10 is involved in t(1;14) (p22; q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 1999; 96: 35-45.
42. 42 Gronbæk K, Straten PT, Ralfkiær E et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998; 92: 3018-24.
43. 43 Geelen FA, Vermeer MH, Meijer CJ et al. bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. J Clin Oncol 1998; 16: 2080-5.
44. 44 Giannotti B, Santucci M. Skin-associated lymphoid tissue (SALT)-related B-cell lymphoma (primary cutaneous B-cell lymphoma). A concept and a clinicopathologic entity. Arch Dermatol 1993; 129: 353-5.
45. 45 Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-7.
46. 46 Beylot-Barry M, Vergier B, DeMascarel A et al. p53 oncoprotein expression in cutaneous lymphoproliferations. Arch Dermatol 1995; 131: 1019-24.
47. 47 Ichikawa A, Kinoshita T, Watanabe T et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997; 337: 529-34.
48. 48 Martinez Delgado B, Fernandez Piqueras J, Garcia MJ et al. Hypermethylation of a 5′ CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia 1997; 11: 425-8.